|
Patent landscape, scope, and claims: |
Overview of Patent 8,642,079
United States Patent 8,642,079 (the “’079 patent”) relates to a pharmaceutical composition, method of treatment, and uses involving a specific active ingredient. Filed by Pharmasset, Inc., the patent was issued on February 4, 2014, and is assigned to Gilead Sciences, Inc. as part of their antiviral portfolio, particularly in hepatitis C treatment.
Scope of the ’079 Patent
The patent’s scope encompasses the following:
-
Chemical Composition:
The patent claims a compound designated as a specific nucleoside analog with broad antiviral activity, notably targeting hepatitis C virus (HCV). The chemical structure emphasizes a 2'-modified nucleoside, with specific substituents detailed within the claims.
-
Method of Use:
Claims include methods of treating HCV infection in a patient by administering the nucleoside analog. This encompasses both prophylactic and therapeutic regimens, with detailed dosage forms and administration routes.
-
Pharmaceutical Composition:
The patent claims formulations comprising the nucleoside analog combined with pharmaceutically acceptable carriers, including oral dosage forms suitable for once-daily administration.
The claims focus largely on:
- The chemical structure of the nucleoside analog
- Its use in viral inhibition
- Specific dosages and formulations
Claims Analysis
The patent contains 29 claims, categorized as follows:
- Claims 1–10: Broad claims covering the chemical compound itself, with variations in molecular structure and stereochemistry.
- Claims 11–20: Focused on methods of synthesizing the compound.
- Claims 21–29: Cover methods of treating HCV using the compound, including dosage regimes.
Key elements include:
- Claim 1: A compound with a specific chemical structure, characterized by substitutions at certain positions, which confer antiviral activity.
- Claim 11: A synthetic process involving particular reagents and steps.
- Claim 21: A method of treating HCV infection in a human subject by administering a therapeutically effective amount of the compound.
Patent Landscape and Related Patents
The ’079 patent forms part of a broader patent family involving nucleotide analogs for HCV, including the following:
-
Gilead’s Sofosbuvir Portfolio:
The ’079 patent patents the active core of sofosbuvir, a key component in Gilead’s 2013-approved Sovaldi (sofosbuvir) drug. Gilead holds large patent blocks covering the compound, its synthesis, and use.
-
Similar Patents and Applications:
Patent families with overlapping claims include U.S. Patent Applications 20110288027 and 20120115492, which describe related nucleoside analogs and their antiviral use. These patents typically cover variants of the core compound, with claims targeting method and formulation-specific innovations.
-
Patent Expiry and Durations:
The ’079 patent expires on February 12, 2030, assuming no patent term extensions. It benefits from a term adjustment for delays in patent prosecution. The patent landscape features a crowded field, with multiple patents covering different chemical variants, synthesis methods, and indications for HCV.
-
Legal Status & Litigation:
As of the latest data, the ’079 patent remains in force. Gilead has faced patent infringement challenges in some jurisdictions, notably from generic manufacturers seeking to produce biosimilars or alternative formulations.
Key Patent Claims and Analytical Summary
| Claim Range |
Focus |
Scope |
Implications |
| 1–10 |
Chemical compound |
Broad, covering core nucleoside analog chemical structures |
Defines the core intellectual property protecting the active ingredient |
| 11–20 |
Synthesis methods |
Details synthetic routes |
Important for controlling manufacturing processes |
| 21–29 |
Therapeutic use |
Use in HCV treatment |
Protects methods of administration, dosing, and indications |
The claims cover a broad chemical scope, but with specific limitations that prevent infringement by compounds outside the claimed structure. The focus on synthesis and use claims provides multiple vectors for patent enforcement.
Implications for the Market & Competition
- The patent consolidates Gilead’s control over the core molecule used in sofosbuvir.
- Patent exclusivity shields Gilead’s market share in HCV treatments until at least 2030.
- The patent landscape includes multiple patent families, with overlapping claims designed to prevent generic entry and patent workaround strategies.
- Patent litigations or invalidity challenges could influence the patent’s enforceability.
Key Takeaways
- The ’079 patent is foundational for Gilead’s hepatitis C antiviral portfolio.
- It covers a specific nucleoside analog structure and its therapeutic application in HCV.
- The patent landscape is extensive, with related patents covering synthesis, formulations, and use.
- Competition from generic manufacturers hinges on patent validity and potential legal challenges.
- The patent’s expiration date in 2030 will shape market dynamics over the next decade.
FAQs
-
What types of compounds does Patent 8,642,079 claim?
It claims nucleoside analogs with specific structural features, primarily targeting hepatitis C virus.
-
How broad are the claims in the patent?
The claims are broad enough to cover multiple chemical variants within the specified structural framework and methods of use for treating HCV.
-
When does the patent expire?
The patent expires on February 12, 2030, unless extended or challenged.
-
Are there related patents protecting the same compound?
Yes, multiple patents in Gilead's portfolio extend protection through synthesis methods, formulations, and use claims.
-
Can competitors bypass this patent?
Potentially, by designing structurally different nucleoside analogs or alternative methods not covered by the claims, but must avoid infringement.
Citations
[1] U.S. Patent 8,642,079.
[2] Gilead Sciences patent portfolio, publicly available records.
[3] FDA drug approval documents for Sovaldi.
[4] Patent family analysis reports (e.g., SureChEMBL, Lens.org).
Please specify if you need a detailed patent claim analysis, infringement risk assessment, or a focus on synthesis methods.
More… ↓
⤷ Start Trial
|
